Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > does she know something, the rest of you don't?

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon May 15, 2022 8:57am

145 Views

Post# 34684692

RE:RE:RE:RE:does she know something, the rest of you don't?

I'm sure the dumpster, will come back next week or so saying he sold at peak of a 5% rise lmao!

I don't expect much movement till at least September.

MrMugsy wrote:

Duster340 wrote: 20K worth of shares is a good size chunk. we will see if there is more buying over the next week or so. good time to get in before the price goes up.

I still think many at ATE are sitting on news.
CITAGENIX being sold was hardly news - we knew by IRFS 5 rules that a sale was coming in 2022.
IMO.